Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Phase 1 Completed 13 enrolled Alexion Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.

Timeline

Start: 2022-06-29
Primary completion: 2023-05-31
Completion: 2023-05-31

Publications

Hu S, Lee K, He JC, Fan Y. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2026 Mar 10. doi: 10.2215/CJN.0000001053. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefurulimab	Monoclonal antibody	1500 mg	Subcutaneous

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Summary

Timeline

Publications

Drugs

Indications